Pfizer Corporation

Osi Pharmaceuticals, Inc.

Other

Pfizer Products Inc.

Timothy Norris

John F Lambert

Jeffrey W Raggon

Megan E Hnatow

Ravi Mysore Shanker

Richard D Connell

Peter Robert Rose

James Dale Moyer

Shama Kajiji

Sandra Leta Silberman

Douglas John Meldrum Allen

Barbara A Foster

Karen J Ferrante

Dinos Paul Santafianos

Michael J Morin

Tamim F Braish

Keith Michael DeVries

Darrell E Fox

Douglas J M Allen

Michael Jon Gumkowski

Douglas J Allen

Richard S Lehner

Thomas A Morris

Phillip James Johnson

David B Joseph

Roberto Colon-Cruz

Troy Anthony Appleton

Lynne A Handanyan

David Joseph Muehlbauer

James J McGarry

Allen J Douglas

Dinos P Santafianos

Robert L Hendrickson

Richard Shelton Lehner

The present invention relates to the anhydrous and hydrate forms of N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine mesylate. The invention also relates to pharmaceutical compositions containing N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine mesylate and to methods of treating hyperproliferative disorders, such as cancer, by administering N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine mesylate.

N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine mesylate anhydrate and monohydrate

A method of monotherapy for a subject suffering from abnormal cell growth expressing the epidermal growth factor receptor (EGFR) which comprises orally administering to the subject a therapeutically effective amount of a crystalline polymorph of the hydrochloride salt of N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine so as to treat the subject.

Treating abnormal cell growth with a stable polymorph of N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine hydrochloride

A process for preparing acyl derivatives as prodrugs of 5-(2-(4-(1,2 benzisothiazole-3-yl)-1-piperazinyl)ethyl-6-chloro-1,3-dihydro-2H-indol-2-one and pharmaceutically acceptable acid addition salts and methods of use as an antipsychotic.

Acyl derivatives of 5-(2-(4-(1,2 benzisothiazole-3-yl)-1-piperazinyl)ethyl)-6-chloro-1,3-dihydro-2h-indol-2-one having neuroleptic activity

The present invention relates to a stable crystalline form of N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine hydrochloride designated the B polymorph, its production in essentially pure form, and its use. The invention also relates to the pharmaceutical compositions containing the stable polymorph B form of N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine as hydrochloride, as well other forms of the compound, and to methods of treating hyperproliferative disorders, such as cancer, by administering the compound.

Stable polymorph on N-(3-ethynylphenyl)-6, 7-bis (2methoxyethoxy)-4-quinazolinamine hydrochloride, methods of production, and pharmaceutical uses thereof

Preparation of sodium-hydrogen exchanger type-1 inhibitors

N-(3-ethynylphenylamino)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine mesylate anhydrate and monohydrate

Processes and intermediates for preparing anti-cancer compounds

Trovafloxacin acid salts are prepared via the hydrolysis of imine intermediates using mineral acid including, but not limited to, methanesulfonic acid, ethanesulfonic acid, benzenesulfonic acid, nitric acid, sulfuric acid, phosphoric acid, hydrochloric acid, hydrobromic acid, tartaric acid, citric acid, acetic acid, and maleic acid. Trovafloxacin acid salts are useful as antibiotic agents.

Process for preparing trovafloxacin acid salts

Process for making 5-lipoxygenase inhibitors having varied heterocyclic ring systems

Two crystalline polymorphic forms of (2-Benzhydryl-1-azo-bicyclo(2.2.2&rsqb;Octyl-3-yl)-(5-iso-propyl-2-methoxybenzyl)amine dihydrochloride dihydrate are Form I and Form II. The pharmaceutical composition containing at least are of these polymorphs has advantageous stability for formulation to treat emesis in patients receiving chemotherapy. The administration of this pharmaceutical composition is conventional oral by preferably tablet or capsule or intravenous. A method of making Forms I and II is also disclosed.

Polymorphs of a crystalline azo-bicyclo 2,2,2 OCT-3-yl amine dihydrochloride and their pharmaceutical compositions

A process is described for preparing a compound of Formula (1.3.0):

This invention relates to zopolrestat monohydrate and polymorphs thereof. This invention also relates to processes for preparing zopolrestat monohydrate, for preparing polymorphs thereof and for preparing anhydrous zopolrestat. This invention also relates to compositions comprising zopolrestat monohydrate and to methods of using zopolrestat monohydrate and compositions thereof to treat diabetic complications such as diabetic cataracts, diabetic retinopathy or diabetic neuropathy, lower blood lipid levels or blood uric level.

Polymorph of zopolrestat monohydrate

Antibacterial quinolone carboxylic acids and naphthyridone carboxylic acids, having an external amino group attached to their 7-substituent are prepared without the use, and subsequent removal, of blocking groups on the external amino group. In a preferred embodiment, the naphthyridone carboxylic acid is the antibiotic trovafloxacin.

Process for preparing quinolone and naphthyridone carboxylic acids

Growing community of inventors

Gales Ferry, CT, United States of America

Timothy Norris